Followers | 439 |
Posts | 45331 |
Boards Moderated | 4 |
Alias Born | 05/11/2008 |
Saturday, February 27, 2021 1:52:54 PM
Prior to Cytocom, Mike was the CEO and Director of Armis Biopharma (aka CHD Biosciences). Armis is a multi-product development-stage healthcare company that has created a technology platform for the prevention and treatment of topical infectious disease. In his role, Mike was responsible for day-to-day operations, executing a profitable growth strategy, obtaining global product approvals, overseeing intellectual property strategy, product commercialization, business development and financing.
Prior to his work at Armis, Mike served in senior management roles at multiple life science companies. Specifically, Mike was one of the founders and on the management team of Vessix Vascular, Inc. in Laguna Hills California from 2011 to 2012. As a result of his work at Vessix Vascular the Company was acquired for $435M by Boston Scientific. Before his time at Vessix Vascular, Mike was Global Head of Regulatory at Acclarent that was acquired by Johnson & Johnson from 2010 – 2011 and assisted in the integration of the $785M acquisition of Acclarent and their five product lines and driving the global revenue growth of the Ethicon franchise for ENT products.
https://www.cytocom.com/about/
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM